September 7 marks World Duchenne Awareness Day, dedicated to raising awareness of Duchenne muscular dystrophy (DMD), a rare, progressive genetic disorder that causes muscle degeneration and weakness, primarily affecting children. While significant advances have been made, there is still an urgent need for innovative therapies and continued collaboration to improve outcomes for patients and their families.
At ASPHALION, we are committed to supporting the rare disease community by helping bring innovative treatments closer to the people who need them. As a regulatory affairs consultancy, we partner with companies throughout the entire medicine lifecycle, providing end-to-end regulatory support—from early development and clinical phases through marketing authorization, lifecycle management, and beyond.
Asphalion is proud to have been a regulatory partner for several projects developing new treatments for DMD and has hosted DMD patient groups as part of our commitment to patient and public engagement.
This World Duchenne Awareness Day, we reaffirm our commitment to advancing innovation, supporting scientific progress, and helping make a meaningful difference for patients living with Duchenne and other degenerative diseases.
Contact us for further information: [email protected]
